Jupiter Wealth Management LLC Sells 200 Shares of Merck & Co., Inc. (NYSE:MRK)

Jupiter Wealth Management LLC decreased its position in Merck & Co., Inc. (NYSE:MRK) by 1.1% during the third quarter, Holdings Channel reports. The fund owned 17,300 shares of the company’s stock after selling 200 shares during the period. Merck & Co., Inc. comprises approximately 1.0% of Jupiter Wealth Management LLC’s investment portfolio, making the stock its 27th biggest position. Jupiter Wealth Management LLC’s holdings in Merck & Co., Inc. were worth $1,965,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the business. Jaffetilchin Investment Partners LLC raised its position in Merck & Co., Inc. by 2.9% in the third quarter. Jaffetilchin Investment Partners LLC now owns 27,331 shares of the company’s stock worth $3,104,000 after acquiring an additional 766 shares during the period. Delta Financial Advisors LLC increased its stake in shares of Merck & Co., Inc. by 28.0% in the 3rd quarter. Delta Financial Advisors LLC now owns 11,470 shares of the company’s stock worth $1,303,000 after purchasing an additional 2,506 shares in the last quarter. Catalytic Wealth RIA LLC raised its holdings in Merck & Co., Inc. by 21.0% in the 3rd quarter. Catalytic Wealth RIA LLC now owns 21,463 shares of the company’s stock worth $2,437,000 after purchasing an additional 3,731 shares during the period. Peregrine Asset Advisers Inc. lifted its position in Merck & Co., Inc. by 9.5% during the third quarter. Peregrine Asset Advisers Inc. now owns 15,585 shares of the company’s stock valued at $1,770,000 after purchasing an additional 1,350 shares in the last quarter. Finally, Ridgecrest Wealth Partners LLC grew its holdings in Merck & Co., Inc. by 3.4% during the third quarter. Ridgecrest Wealth Partners LLC now owns 11,658 shares of the company’s stock valued at $1,324,000 after purchasing an additional 386 shares during the period. Institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. Trading Down 0.0 %

MRK stock opened at $102.90 on Monday. The firm has a market cap of $260.30 billion, a PE ratio of 21.58, a price-to-earnings-growth ratio of 1.47 and a beta of 0.40. The firm has a fifty day moving average price of $110.74 and a 200 day moving average price of $119.94. The company has a debt-to-equity ratio of 0.79, a quick ratio of 1.22 and a current ratio of 1.36. Merck & Co., Inc. has a fifty-two week low of $98.60 and a fifty-two week high of $134.63.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings results on Thursday, October 31st. The company reported $1.57 EPS for the quarter, beating analysts’ consensus estimates of $1.50 by $0.07. Merck & Co., Inc. had a net margin of 19.23% and a return on equity of 36.42%. The firm had revenue of $16.66 billion during the quarter, compared to the consensus estimate of $16.47 billion. During the same quarter last year, the firm earned $2.13 EPS. The firm’s revenue for the quarter was up 4.4% compared to the same quarter last year. Sell-side analysts anticipate that Merck & Co., Inc. will post 7.75 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently commented on MRK shares. Truist Financial decreased their price objective on Merck & Co., Inc. from $132.00 to $130.00 and set a “buy” rating on the stock in a research note on Thursday. UBS Group lowered their price target on shares of Merck & Co., Inc. from $142.00 to $136.00 and set a “buy” rating on the stock in a report on Wednesday, October 9th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $155.00 price target on shares of Merck & Co., Inc. in a research report on Thursday, October 3rd. Citigroup decreased their price objective on shares of Merck & Co., Inc. from $140.00 to $130.00 and set a “buy” rating on the stock in a research report on Friday, October 25th. Finally, BMO Capital Markets dropped their target price on shares of Merck & Co., Inc. from $150.00 to $136.00 and set an “outperform” rating for the company in a report on Friday, November 1st. One analyst has rated the stock with a sell rating, four have given a hold rating, ten have issued a buy rating and four have assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $130.86.

Merck & Co., Inc. Profile

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.